CAR T Cells in Mesothelin-Expressing Breast Cancer

• ClinicalTrials.gov Identifier: NCT05623488
• Recruitment Status: Recruiting
• First Posted: November 21, 2022
• Last Update Posted: February 8, 2023
• Sponsor: University of Pennsylvania
• Information provided by (Responsible Party): University of Pennsylvania

Study Description

Brief Summary:

Phase 1 - Safety and Proof of Concept

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: huCART-meso cells; Device: Mesothelin Expression Testing	Phase 1

Detailed Description:

This is a phase I study to establish the safety and feasibility of lentiviral transduced CAR T cell products in patients with mesothelin expressing breast cancer. This study will be initiated as a single cohort (described below), however the adaptive design will allow for additional disease indications and other investigational CAR T cell products to be explored as separate cohorts under this protocol in the future.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer
• Actual Study Start Date: February 6, 2023
• Estimated Primary Completion Date: February 2025
• Estimated Study Completion Date: February 2038

Arms and Interventions

Arm	Intervention/treatment
Experimental: Dose Level 1; 3.00 x 10^7 CAR T cells administered intratumoral	Drug: huCART-meso cells; Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains; Device: Mesothelin Expression Testing; Laboratory Developed Test
Experimental: Dose Level -1; 3.00 x 10^6 CAR T cells administered intratumoral	Drug: huCART-meso cells; Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains; Device: Mesothelin Expression Testing; Laboratory Developed Test

Outcome Measures

Primary Outcome Measures :

1. Occurrence of treatment-limiting toxicities (TLTs) [ Time Frame: 90 days ]
2. Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0. [ Time Frame: 15 years ]

Secondary Outcome Measures :

1. Proportion of manufacturing product that do not meet the release criteria. [ Time Frame: 60 days ]
   manufacturing failures
2. Proportion of the products that meet the target dose. [ Time Frame: 60 days ]
3. Proportion of enrolled subjects that receive study treatment. [ Time Frame: 60 days ]
4. Proportion of eligible subjects that receive study treatment [ Time Frame: 60 days ]
5. Proportion of subjects for which standard of care treatment is not impacted due to CAR T cell related toxicity. [ Time Frame: 90 days ]
6. Kinetics of expansion and persistence of infused cells by flow cytometry. [ Time Frame: 90 days ]
7. Kinetics of expansion and persistence of infused cells by quantitative PCR. [ Time Frame: 90 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients with locally advanced unresectable or metastatic triple-negative breast cancer as confirmed by all of the following:

   1. ER-negative or low-ER positive (≤ 10% by IHC)
   2. PR-negative or low-PR positive (≤ 10% by IHC)
   3. HER2 negative by IHC/FISH
2. Patients with an accessible lesion that can be targeted for both intratumoral injection and surgical excision/biopsy by either a surgeon or interventional radiology.
3. Confirmed tumor mesothelin expression by ≥ 10% of malignant cells by IHC.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5. Adequate organ and bone marrow function defined as:

   1. Bilirubin ≤ 2.0 x ULN
   2. Serum Creatinine ≤ 1.5 x ULN
   3. ALT/AST ≤ 3 x ULN
   4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air
   5. Left Ventricle Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram
6. Male and female patients ≥ 18 years of age.
7. Provides written informed consent.
8. Subjects of reproductive potential must agree to use acceptable birth control methods

Exclusion Criteria:

1. Active invasive cancer other than the study-targeted malignancy.

2. Evidence of active hepatitis B or hepatitis C. The following would not qualify as an active infection, thus would not exclude the subject from participating:

   1. Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis for potential HBV reactivation.
   2. Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.
3. Patients with ongoing or active infection.
4. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10 mg/day of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
5. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (≤ 10mg daily equivalent of prednisone). Use of inhaled or topical steroids is allowable.
6. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).
7. Pregnant or breastfeeding women.
8. Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist if cardiac issues are suspected.

9. Patients with significant lung disease as follows:

   1. Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden.
   2. Patients with radiographic and/or clinical evidence of active radiation pneumonitis.
   3. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc).
10. Patients with active central nervous system (CNS) involvement. Screening for this (e.g. lumbar puncture, brain MRI, etc) is not required unless the patient is symptomatic and/or radiographic findings are present.

Contacts and Locations

Contacts

Contact: Abramson Cancer Center Clinical Trials Service; 855-216-0098; PennCancerTrials@emergingmed.com

Locations

United States, Pennsylvania

University of Pennsylvania; Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contact: Abramson Cancer Center Clinical Trials Service 855-216-0098 PennCancerTrials@emergingmed.com

Sponsors and Collaborators

University of Pennsylvania

Investigators

• Principal Investigator: Julia Tchou, MD, PhD; University of Pennsylvania

More Information

• Responsible Party: University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT05623488
• Other Study ID Numbers: UPCC# 15122, IRB # 852205
• First Posted: November 21, 2022
• Last Update Posted: February 8, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases